Literature DB >> 27128308

Sesamin inhibits lipopolysaccharide-induced inflammation and extracellular matrix catabolism in rat intervertebral disc.

Kang Li1, Yan Li1, Bo Xu1, Lu Mao1, Jie Zhao1.   

Abstract

Intervertebral disc (IVD) degeneration contributes to most spinal degenerative diseases, while treatment inhibiting IVD degeneration is still in the experimental stage. Sesamin, a bioactive component extracted from sesame, has been reported to exert chondroprotective and anti-inflammatory effects. Here, we analyzed the anti-inflammatory and anti-catabolic effects of sesamin on rat IVD in vitro and ex vivo. Results show that sesamin significantly inhibits the lipopolysaccharide (LPS)-induced expression of catabolic enzymes (MMP-1, MMP-3, MMP-13, ADAMTS-4, ADAMTS-5) and inflammation factors (IL-1β, TNF-α, iNOS, NO, COX-2, PGE2) in a dose-dependent manner in vitro. It is also proven that migration of macrophages induced by LPS can be inhibited by treatment with sesamin. Organ culture experiments demonstrate that sesamin protects the IVD from LPS-induced depletion of the extracellular matrix ex vivo. Moreover, sesamin suppresses LPS-induced activation of the mitogen-activated protein kinase (MAPK) pathway through inhibiting phosphorylation of JNK, the common downstream signaling pathway of LPS and IL-1β, which may be the potential mechanism of the effects of sesamin. In light of our results, sesamin protects the IVD from inflammation and extracellular matrix catabolism, presenting positive prospects in the treatment of IVD degenerative diseases.

Entities:  

Keywords:  extracellular matrix; inflammation; intervertebral disc; lipopolysaccharide; organ culture; sesamin

Mesh:

Substances:

Year:  2016        PMID: 27128308     DOI: 10.1080/03008207.2016.1182998

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  7 in total

1.  Sesamin inhibits IL-1β-stimulated inflammatory response in human osteoarthritis chondrocytes by activating Nrf2 signaling pathway.

Authors:  Pengyu Kong; Guanghua Chen; Anlong Jiang; Yufu Wang; Chengchao Song; Jinpeng Zhuang; Chunyang Xi; Guangxi Wang; Ye Ji; Jinglong Yan
Journal:  Oncotarget       Date:  2016-12-13

2.  Sesamin Enhances Nrf2-Mediated Protective Defense against Oxidative Stress and Inflammation in Colitis via AKT and ERK Activation.

Authors:  Xupeng Bai; Xiaoli Gou; Peiheng Cai; Chuncao Xu; Lin Cao; Zhongxiang Zhao; Min Huang; Jing Jin
Journal:  Oxid Med Cell Longev       Date:  2019-08-26       Impact factor: 6.543

Review 3.  Painful intervertebral disc degeneration and inflammation: from laboratory evidence to clinical interventions.

Authors:  Feng-Juan Lyu; Haowen Cui; Hehai Pan; Kenneth Mc Cheung; Xu Cao; James C Iatridis; Zhaomin Zheng
Journal:  Bone Res       Date:  2021-01-29       Impact factor: 13.567

Review 4.  The Proteolysis of ECM in Intervertebral Disc Degeneration.

Authors:  Huaizhen Liang; Rongjing Luo; Gaocai Li; Weifeng Zhang; Yu Song; Cao Yang
Journal:  Int J Mol Sci       Date:  2022-02-02       Impact factor: 5.923

Review 5.  Targeting Oxidative Stress and Inflammation in Intervertebral Disc Degeneration: Therapeutic Perspectives of Phytochemicals.

Authors:  Liang Kang; Huaqing Zhang; Chongyu Jia; Renjie Zhang; Cailiang Shen
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

6.  Berberine suppresses apoptosis and extracellular matrix (ECM) degradation in nucleus pulposus cells and ameliorates disc degeneration in a rodent model.

Authors:  Yu Chen; Zengming Zheng; Jianle Wang; Chengxuan Tang; Sinan Khor; Jian Chen; Xibang Chen; Zengjie Zhang; Qian Tang; Chenggui Wang; Yiting Lou; Zhouguang Wang; Jian Xiao; Xiangyang Wang
Journal:  Int J Biol Sci       Date:  2018-04-30       Impact factor: 6.580

7.  Molecular Mechanism of Xixin-Ganjiang Herb Pair Treating Chronic Obstructive Pulmonary Disease-Integrated Network Pharmacology and Molecular Docking.

Authors:  Ping Huang; Tao Huang; Deshun Li; Lintao Han; Zhenxiang Zhou; Fang Huang; Jingjing Li; Jiajia Wu; Yan Ye; Qiong Wang; Bailu Duan
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-10       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.